Daily Low-Dose Aspirin May Reduce Risk of Some Cancers

This article originally appeared here.
Share this content:
Daily Low-Dose Aspirin May Reduce Risk of Some Cancers
Daily Low-Dose Aspirin May Reduce Risk of Some Cancers

FRIDAY, March 4, 2016 (HealthDay News) -- Taking low-dose aspirin every day may lower the overall risk of cancer by 3 percent, mostly due to larger reductions seen in risk for colon and gastrointestinal tumors, according to research published online March 3 in JAMA Oncology.

Andrew Chan, M.D., M.P.H., from Massachusetts General Hospital in Boston, and colleagues looked at the link between aspirin and cancer among 135,965 women and men who took part in the long-term Nurses' Health Study and the Health Professionals Follow-up Study. During more than 30 years of follow-up, there were 20,414 cancers among 88,084 women and 7,571 cancers among 47,881 men.

Taking low-dose aspirin two times or more per week was associated with a 3 percent lower risk for cancer overall, mostly due to a 15 percent lower risk for gastrointestinal cancers and a 19 percent lower risk for cancers of the colon and rectum. The benefit was only seen after six years of taking aspirin almost daily, the researchers found. Aspirin was not associated with a lower risk for other major cancers, such as breast, prostate, or lung cancer.

"There is scientific evidence that aspirin has an effect on certain biological pathways that can result in cancer," Chan told HealthDay. And it also reduces inflammation and the amount of some cancer-causing proteins. "The evidence has reached the point that it may be useful to consider using aspirin to prevent colon cancer," Chan said. "But we are still not at a point where the general population should take aspirin for cancer prevention."

One author disclosed financial ties to Bayer Healthcare, Pfizer, and Pozen.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths